

CURRICULUM VITAE

Personal Information:

Name: STEPHEN S. KIRZINGER, M.S., M.D., FAAN

Home Address: 1106 Colonel Anderson Parkway
Louisville, Kentucky 40222

Office Address: Department of Neurology
University of Louisville
School of Medicine
Health Sciences Center
Louisville, Kentucky 40292

University Neurologists, PSC
401 East Chestnut Street—Suite 510
Louisville, Kentucky 40202

Kentucky Neuroscience Research
401 East Chestnut Street—Suite 520
Louisville, Kentucky 40202

Telephone: 502-419-4732

FAX: 502-852-6344

Email: stephen.kirzinger@gte.net

Education:

Undergraduate:	1964-1968	Centre College of Kentucky Danville, Kentucky Bachelor of Arts Degree Chemistry Major
Graduate Training:	1968-1969	University of North Carolina Chapel Hill, North Carolina Doctor of Philosophy Program Department of Biochemistry (Interrupted by military service)
	1974-1977	University of Louisville Louisville, Kentucky Master of Science - Biochemistry
	1973-1977	University of Louisville Louisville, Kentucky Doctor of Medicine
Post-Graduate Training:	1977-1978	Walter Reed Army Medical Center Washington, D.C. Internship-Categorical Psychiatry
	1978-1981	Walter Reed Army Medical Center Washington, D.C. Residency-Adult Neurology

Academic Appointments:

1999-2003:	Assistant Clinical Professor Department of Neurology University of Louisville
2004-June 2009:	Assistant Professor Department of Neurology University of Louisville

July 2009- Present: Associate Professor
Department of Neurology
University of Louisville

Professional Experience:

July 1981 - June 1985
Chief, Neurology Service
Ireland Army Community Hospital
Fort Knox, Kentucky

July 1985 - January 1991
Neuroscience Associates, PSC.
Louisville, Kentucky

January 1991 - May 1991
Operation Desert Storm
Acting Chief, Neurology Service
Ireland Army Community Hospital
Fort Knox, Kentucky

May 1991 – January 2004
Partner
Neuroscience Associates, PSC.
Louisville, Kentucky 40207

1997 – December 2003
Louisville Neuroscience Research Center
Medical Director
Louisville, Kentucky 40207

September 1997 – 15 July 2009
Baptist Hospital East - Multiple Sclerosis Center
Medical Director
Louisville, Kentucky 40207

January 2004 – June 2009
Assistant Professor
Department of Neurology
University of Louisville Medical School
Louisville, Kentucky 40292

July 2009- Present
Associate Professor
Department of Neurology
University of Louisville School of Medicine
Louisville, Kentucky 40292

January 2004 – Present
Medical Director, MS Care Center Program
University Neurologists, PSC
401 East Chestnut Street, Suite 510
Louisville, Kentucky 40202

Military Status: United States Army Reserve - Retired
Rank: Colonel
29 years of active and reserve service
MOS: 6OV

Military Training/Assignments: September 1969 - November 1969
Basic Training - Fort Dix, New Jersey
November 1969 - January 1970
Advanced Individual Training, Combat Engineer
Fort Leonard Wood, Missouri
January 1970 - July 1970
Engineer Officer Candidate School
Fort Belvoir, Virginia
Commissioned Second Lieutenant
July 1970 - September 1970
Basic Ordnance Officer Course
Aberdeen Proving Grounds, Maryland
September 1970 - December 1970
Special Weapons Officer School
Sandia Base, New Mexico
January 1971 - July 1972
823rd Ordnance Company - Fort Riley, Kansas
July 1972 - April 1973
Human Relations/Civil Affairs Officer
20th Support Group - Ascom, Korea
April 1973 - August 1973
Equal Opportunity Officer
227th Maintenance Battalion
Seoul Korea
August 1973 - June 1977

Health Professions Scholarship Program
(Reserve Status)
July 1977 - June 1981
Walter Reed Army Medical Center
Washington, D.C.
July 1981 - June 1985
Chief, Neurology Service
Ireland Army Community Hospital
Fort Knox, Kentucky
June 1985 - October 1988
Second Army Medical Augmentation Detachment
Fort Gillem, Georgia (Reserve)
October 1988 - December 1991
5010th U.S. Army Hospital
Louisville, Kentucky (Reserve)
January 1991 - May 1991
Acting Chief, Neurology Service
Ireland Army Community Hospital
Fort Knox, Kentucky
May 1991 - October 1998
5010th U.S. Army Hospital
Louisville, Kentucky (Reserve)
October 1998 - Retired Reserve

Board Certification and Licensure:

Board Certification: American Board of Psychiatry and Neurology,
Diplomate in Adult Neurology
November 1982

Licensures: Maryland - D22509 August 1978
Kentucky - K21854 February 1982
Indiana - 01034371 June 1985

Hospital Staff Affiliations: Active Staff:
Baptist Hospital East
University Hospital, University of Louisville
Norton Suburban Hospital
Norton Hospital I

Consulting Staff:
St. Mary's Hospital and Jewish Hospital

Professional Memberships and Activities:

Professional Memberships:

American Academy of Neurology
Active Member: 1979- 2003
Fellow: Jan 2004 to Present

American Medical Association, No. 0200 2770 558
1985 to Present

Kentucky Medical Association
1982 to Present
Delegate KMA House of Delegates
1995,1996,1997,1998,1999,2000,2002,2003,2004,2005,
2006,2008

Greater Louisville Medical Society
Member-1985 to Present
Board of Governors- 1997 through Present
Legislative Committee- 1992, 1993, 1994
Medical Society Professional Services-
1994 through Present
- Treasurer 1996, 1997
- President 1997 to Present
Managed Care Committee
1997,1998,1999,2000,2001,2002
Uninsured Task Force Committee
2003, 2004

European Neurological Society
September 1998 to Present

American Stroke Association
February 1999 to 2006

Stroke Council Member
National Stroke Association
June 1999 to 2006

Commonwealth Neurology Society
Board of Directors- 2007 to Present

Association of Clinical Research Professionals
2001, 2002, 2003, 2004
ID # 90282

American Heart Association
Membership # 100000701245

Kentucky- Southeast Indiana Chapter of the
National Multiple Sclerosis Society

Board Member - 1993 to Present
Executive Committee -1996, 1997, 1998, 2002, 2003,
2004, 2005, 2006, 2007, 2008
Clinical Advisory Committee- 1993- Present
Chair 2001 – June 2008
Services Committee 1995-1998; 2005-2007
Chair 1996 – 1998

Consortium of Multiple Sclerosis Centers
Member 1997- Present
Board of Directors- June 2008- Present
Vice Chair- Education Committee June 2008-

Present

Education Committee 2004-2007
Clinical Care Committee 1997, 1998, 1999
NARSCOM

Professional Activities:

Past-President, Spinoscopy of Louisville, PSC
Non-Invasive Evaluation of Spinal Function

Baptist Hospital East Multiple Sclerosis Center
Medical Director- 1997- Present

Gateway Rehabilitation Hospital Multiple Sclerosis
Clinic- Medical Director- 2006- March 2008

UL HealthCare Multiple Sclerosis Center
Medical Director-
July 2008- Present

America's Doctor, Inc.- Clinical Research Organization

Neuroscience Network – 1997-2001

Member of:

- Physician Advisory Board until 2000
- Neuroscience Board of Governors
- Finance Committee

Speakers Bureau:

- EISAI Pharmaceutical
- Pfizer Pharmaceutical, Inc.
- Biogen-Idec
- Novartis Pharmaceutical
- Bayer Healthcare
- Teva Neuroscience
- EMD Serono Pharmaceutical
- Forest Pharmaceutical
- Medtronic Neuromodulation

Honors and Awards:

Centre College Honor Scholarship - 1964-68

Omicron Delta Kappa Leadership Fraternity

May, 1968- Present

Department of Biochemistry Research Fellowship

University of North Carolina, Chapel Hill, NC

May 1968- May 1969

Phi Kappa Phi Honor Society - April 1978

Medical/Graduate School Research Day Participant

University of Louisville - 1975

Graduate School Dean's Citation - May 1978

US Army Commendation Medal-May 1973, June 1985

US Army Achievement Medal - May 1991

US Army Meritorious Service Medal - October 1998

Fellow, American Academy of Neurology

26 January 2004

Kentucky-Southeast Indiana Chapter of National MS Society

- Community Leadership Award - 1997

- Volunteer of the Month - July 1998

- NMSS Dinner of Champions Honoree- 2005

-Core Value Award of NMSS- November 2006

Community Health Charities

Volunteer of Year – March, 2002

Rev. December 2008
Kentucky/Southern Indiana Multiple Sclerosis Society

National Directory of Who's Who- 2000

Global Directory of Who's Who- May 2007

Journal Editorial Boards, Advisory Councils, Peer Reviewer of Manuscripts:

Editorial Board: *NEURA*
Quarterly Monograph on MS and Parkinson's Disease
2005 to Present

Steering Committee Member
ROBUST MS Study
Bayer HealthCare Pharmaceuticals
2007 to Present

Optimizing Outcomes in Multiple Sclerosis
CME Program- Health Education Alliance, Inc.
Three Phase Newsletter Development Participant
2007-2008

Advisory Councils:
- Teva Neuroscience - Multiple Sclerosis Consultant
- Bayer Healthcare - Multiple Sclerosis Advisory Board
- Biogen Idec- Multiple Sclerosis - Advisory Panel
- EMD Serono Pharmaceutical .

Teaching:

Lecturer on Ophthalmological Manifestations of
Neurological Conditions
Optometry Service, Ireland Army Hospital,
19 July 1983.

Lecturer on Neurological Examination in the Evaluation of Head Trauma
Oral Surgery Teaching Conference,
Dental Department, Ireland Army Hospital,
15 Oct. 1984.

Lecturer on Vascular Disorders of the Brain, Nursing Service,
Sts. Mary and Elizabeth Hospital
Louisville, Kentucky, 1 December 1987.

Lecturer on Alzheimer's Disease
Physicians Noon Conference,
Audubon Hospital, Louisville, Kentucky
23 July 1993.

Faculty at Western Kentucky Adjusters Association Meeting,
Low Back Injuries: A New Approach at Evaluation
Owensboro, Kentucky, 20 September 1993.

Faculty at Kentucky Medical Association Annual Meeting

Carpel Tunnel Syndrome Update,
Kentucky Occupational Medical Association Meeting
Louisville, Kentucky, 30 September 1993.

Lecturer on Alzheimer's Disease: Approach to Therapy,
University of Louisville Medical School,
Department of Family Practice, Grand Rounds
4 March 1994.

Lecturer on a Medico-Legal Approach for Plaintiff and Defense,
Kentucky Closed Head Injury Seminar, sponsored by
Professional Education Systems, Inc.
18-19 January 1996.

Lecturer at Update on Treatment Options,
Louisville Parkinson's Support Group Meeting,
Jefferson Mall, Jewish Hospital Health and
Information Center

25 January 1996.

Lecturer at Update on Multiple Sclerosis
Visiting Nurses Association
4 March 1997

Faculty at Kentucky Academy of Family Physicians
Winter Seminar
Update on Alzheimer's Disease
8-9 March 1997

Faculty at Multiple Sclerosis Issues
Focus on Disability
Biogen - Sponsor
1997 Educational Teleconference
26 June 1997

Lecturer on Multiple Sclerosis Update
Medical Staff CME Presentation
Baptist Hospital East
29 August 1997

Update on Treatment of Parkinson's Disease
Smith Kline Beecham
24 June 1998

Lecturer on Alzheimer's Disease Review
Medical Staff CME Presentation
Baptist Hospital East
30 September 1998

Mental Health Professionals
Multiple Sclerosis Update
19 March 1999

Co-Chair and Faculty at Care of the MS Patient with
Progressive Disease
Kentucky/Southern Indiana Chapter
Multiple Sclerosis Society
Awareness Weekend
12 June 1999

Lecturer on Management of the Newly Diagnosed
Indiana Chapter/Multiple Sclerosis Society

Evansville, Indiana
18 September 1999

Lecturer at Multiple Sclerosis Update
Georgetown MS Town Meeting
Georgetown, Kentucky
7 March 2000

Lecturer on Dementia and Alzheimer's Disease
Central State Hospital Staff, Louisville, Kentucky
Pfizer Pharmaceuticals- Sponsor
1 September 2000

Lecturer for An Update on the Diagnosis and Treatment
of Alzheimer's Disease
Brown Hotel
Novartis Pharmaceuticals- Sponsor
11 October 2000

Lecturer on Spasticity in MS
Baptist Hospital East – Louisville, Kentucky
Physician CME Program
30 March 2001

Reminyl: New Kid On Block in Treatment of
Alzheimer's Disease
Ortho-McNeil Pharmaceutical
Louisville, Kentucky

Lecturer on Update From European Congress on
Treatment and Research in Multiple Sclerosis
Berlex- Sponsor
Napa River Grill – Louisville, Kentucky
October, 2001

Faculty at Recent Advances in Treatment of Multiple
Sclerosis
National Education Conference for Intramed
Educational Group
Marina del Ray, California
14-16 December 2001

Lecturer on Update on Alzheimer's Disease
Communicare, Elizabethtown, Kentucky
Sponsored by Pfizer

11 March 2002

Lecturer for Patient Informational Program on Multiple Sclerosis

Jewish Inn – Louisville, Kentucky
Sponsored by TEVA Neuroscience
20 May 2002

Lecturer at the BHE Multiple Sclerosis Center Program
The Benefit of a Case Management Approach in MS Care. Sponsored by the National MS Society
23 October 2002

Lecturer on Alzheimer's Disease Update – Caregiver Program

Sponsored by Eunoe, Incorporated
Seelbach Hotel – Louisville, Kentucky
16 November 2003

Multiple Sclerosis Three Part Lecture Series
University of Louisville Neurology Residency Program
2004 to Present

Lecturer and Course Development of Spinal Cord Syndromes
4th Year University of Louisville Medical Student Clerkship in Neurology
2004 to Present

Lecturer on MS Treatment Options

Cogenix Patient Program
Martinsville, IN
21 April 2004

Lecturer for MS Disease Modifying Therapies

Berlex Laboratories Direct to Patient Program
Louisville, KY
27 May 2004

Co- Faculty at Worsening MS Program

KY- Southeast IN Chapter of NMSS
Sponsored by Serono
Louisville, KY
28 October 2004

Rev. December 2008

Lecturer on Gearing Up- Living Well With MS
Biogen- Idec
Embassy Suites, Lexington, KY
2 December 2004

Lecturer at the Kentucky- Southeast Indiana Chapter of
NMSS Patient Program,
Louisville, KY
Sponsored by Berlex,
27 May 2004

Lecturer at Multiple Sclerosis Patient Presentation
Louisville, KY
Sponsored by Pfizer
12 October 2004

Lecturer at Worsening MS Patient Program,
Louisville, KY
Sponsored by Serono
28 October 2004

Lecturer at MS Patient Program on New Therapies,
Lexington, KY
Sponsored by Biogen-Idec
2 December 2004

Lecturer at MS Update: For Those Living with MS
and Their Loved Ones
Columbus, OH
Sponsored by COGENIX
12 February 2005

University Internal Medicine Residents Didactic Session
University Hospital,
Louisville, KY
23 February 2005

Lecturer for MSAA Patient Program,
Louisville, KY
Sponsored by Berlex
22 March 2005

Dementia Panel: Diagnosis and Treatment of
Alzheimer's Disease
Louisville, KY

Sponsored by Pfizer
21 April 2005

Lecturer for Movement for Living: MS Patient Program
on Spasticity
Louisville, KY
Sponsored by Medtronic
12 MAY 2005

Kentucky Chapter of NMSS Disability Workshop,
Louisville, KY
Sponsored by Pfizer
17 May 2005

Faculty at Advances in Neurology CME Program:
MS Update,
University of Louisville, The Inn at Jewish Hospital,
Louisville, KY
21 May 2005

Lecturer at BETA MRSC Program:
What you need to know about MRI
Louisville, KY
Sponsored by Berlex
26 July 2005

pw 2/27/06 2:27 PM

Comment: Where?

Lecturer at Pfizer Pharmaceuticals and Kentucky
Southeast Indiana Chapter of National MS Society
Presentation:
Cognitive Aspects of Multiple Sclerosis
Sponsored by Pfizer and Kentucky-Southeast Indiana
Chapter of MS Society
8 September 2005

Lecturer at Lyrica Update
Louisville, KY
Sponsored by Pfizer
2 September 2005

pw 2/27/06 2:32 PM

Comment: Where?

Lecturer at MS Update
Bowling Green, KY
Sponsored by Biogen Idec
20 September 2005

pw 2/27/06 2:33 PM

Comment: Title or topic?

From Diagnosis to Delay: Treating the MS Patient in

Managed Care Environments
Nashville, TN
Educational Grant from Serono and Pfizer
5 October 2005

Faculty at Eisai's Presentation: Roundtable
Discussion of Aricept's Effect on Neuropsychiatric
Aspects of Alzheimer's Disease and Response in
Moderate- Severe Alzheimer's Disease
Louisville, KY
30 November 2005

New Developments in MS Therapy
Louisville, KY
Sponsored by Biogen Idec and Elan
11 September 2006

Lecturer on Spinal Cord Emergencies
Neurology Residents Emergencies Lecture Series
University of Louisville
July, 2007 to Present

Lecturer for Worsening MS: What to Do When MS
Progresses
KY-SE IN Chapter of NMSS
Owensboro, KY
12 September 2007

Lecturer for Namenda: Changing the Treatment
Paradigm in Alzheimer's Disease
Louisville, KY
Sponsored by Forest Pharmaceuticals
23 October 2007

Organizer and Faculty for Multiple Sclerosis and
Cognition
Baptist Hospital East MS Center
Louisville, KY
7 November 2007

Faculty at Advances in MS Management
Bayer HealthCare National Consultants Meeting
Phoenix, AZ
18-20 January 2008

Multiple Sclerosis Overview for Residents
Internal Medicine Department
University of Louisville
Louisville, KY
13 February 2008

Faculty for 16th Annual Pre-Derby U of L Alumni
Conference
Dementia Update
Louisville, KY
26 April 2008

Organizer and Faculty for MS in Balance:
Mind, Body, and Spirit
Louisville, KY
Sponsored by Pfizer and EMD Serono, Inc.
24 June 2008

Fellows/ Service Learning at University of Louisville:

2004	Craig Carter (Summer Medical Student Research Scholar)
2005	Kartik Suresh (Summer Medical Student Research Scholar)
2006	M. Karsten Dengel, M.D. (MS Fellow) Jul thur Dec. Andrew Crush (Summer Medical Student Research Scholar) Honorable Mention- Medical Student Research Poster Research Louisville 10-13 October 2006
2007	M. Karsten Dengel, M.D. (MS Fellow)- Jan thru Jun. Justin Phillips (Summer Research Scholarship- Consortium of Multiple Sclerosis Centers) Dean's Special Commendation- Research Day Poster Amanda Burns (Summer Medical Student Research Scholar) Jenifer Patterson, ARNP (NMSS Nurse Fellowship in MS) Manjari Motaparathi, M.D. (Observership in MS)- Jan to Jun Suma Chand, PhD (Research Assistant)
2008	Andrew Feldman (Summer Research Scholarship- Consortium of Multiple Sclerosis Centers Foundation) Michael Wells (Summer Research Scholarship-

Teaching Responsibilities: Medical Education and Graduate Medical Education:

1. Senior Medical Student Neurology Clerkship: Clinical Experience in Neurology Practice, Monthly each academic year.
2. Senior Medical Student Neurology Clerkship Lecture: Localization of Spinal Cord Lesions: Monthly during academic year.
3. Neurology Residency Neurological Emergencies Series: Spinal Cord Emergencies, yearly
4. Neurology Residency Immunology and Multiple Sclerosis Lecture Series: quarterly
5. Internal Medicine Residents Lecture: Update on Multiple Sclerosis, yearly
6. Neurological Surgery Residency Lecture Series: Differential Diagnosis of Multiple Sclerosis, yearly starting in 2008
7. First and Second Year Medical Student Observerships: five students per year

Abstracts and Presentations:

Oral Presentations: National/International Meetings:

2001: Recent Advances in Treatment of Multiple Sclerosis
National Education Conference for Intramed Education Group
Marina del Ray, California
14-16 December 2001

2008: Advances in MS Management
Bayer HealthCare National Consultants Meeting
Phoenix, AZ
18-20 January 2008

Oral Presentations: Local/Regional Meetings:

1993: Kentucky Medical Association Annual Meeting
Carpel Tunnel Syndrome Update,
Kentucky Occupational Medical Association Annual Meeting
Louisville, Kentucky
30 September 1993

1997: Kentucky Academy of Family Physicians Winter Seminar
Update on Alzheimer's Disease
Bowling Green, KY
8-9 March 1997

Poster Presentations:

National/International Meetings:

2003: American Academy of Neurology, 55th Annual Meeting
D.E. Goodkin and M.V. Lopez-Bresnahan on behalf of the Renew Study Group,
Registry to Evaluate Novantrone®
Effects in Worsening Multiple Sclerosis (RENEW): Status Report March, 2003 –
Honolulu, Hawaii
29 March 29- April 2003

2004: European Neurological Society Fourteenth Meeting
P458: First Phase of Beyond Program: Safety and Tolerability,
P. Coyle, B. Arnason, **S. Kirzinger** et al.
Barcelona, Spain
26-30 June, 2004

European Neurological Society Fourteenth Meeting
P591: MRI Data in Comparison of Two Doses of IFN-Beta: First Phase of Beyond
Program, D. Jeffrey, B. Arnason, **S.Kirzinger** et al. Barcelona, Spain
26-30 June 2004

20th Congress of the European Committee for Treatment and Research in Multiple
Sclerosis
P589 :MRI Outcomes in RRMS: First Phase of Beyond Program, D. Jeffery, B
Arnason, **S.Kirzinger** et al. Vienna, Austria 6-9 October, 2004

20th Congress ofECTRIMS
P579:An Open Label Study Evaluating the Effect of Chronic Interferon Treatment on
the Immunological Response to Influenza Vaccine, S.R. Schwid et al. Vienna,
Austria 6-9 October 2004

2005: American Academy of Neurology 57th Annual Meeting
P05.36:MS Fatigue Response to Modafinil, **S. Kirzinger**, C. Carter, and A. Siegwald. Miami

Beach, Florida 9-16 April 2005

Consortium of MS Centers 19th Annual Meeting

S14: Fatigue Reported by MS Patients and Response to Modafinil, C. Carter, **S. Kirzinger**, and A. Siegwald. Orlando, Florida 1-5 June 2005

Consortium of MS Centers 19th Annual Meeting

S39: Fatigue Assessment in the Usual Care of MS Patients, **S. Kirzinger** and A. Siegwald. Orlando, Florida 1-5 June 2005

Consortium of MS Centers 19th Annual Meeting

W39: Taking "Healthy Steps", J. Naville, D. Nelson, and **S. Kirzinger** Orlando, Florida_1-5 June, 2005

European Neurological Society Fifteenth Meeting

P 485: First Phase of Beyond Program: One Year Interim Analysis, B. Hurwitz, B. Arnason, **S. Kirzinger** et al. Vienna, Austria 18-22 June, 2005

2007: Consortium of MS Centers 21st Annual Meeting

S58: Fatigue and Depression: Relationship to Disease Modifying Therapy, **S. Kirzinger** and A. Siegwald, Washington, D.C. 30 May- 2 June 2007

European Neurological Society Seventeenth Meeting

P284: Depression in MS: Relationship to Disease Modifying Therapy, **S. Kirzinger**, A. Siegwald and A. Crush. Rhodes, Greece 16-20 June 2007

23rd Congress of the European Committee for Treatment and Research in MS

P181: First Phase of Beyond Program: Analysis of 3 Year Data from Open Label, Extension Study, **S. Kirzinger**, B. Arnason, G. Bigley, et al. Prague, Czech Republic 11-14 October 2007

2008: Consortium of Multiple Sclerosis Centers 22nd Annual Meeting

S34: Long Term Effect of Modafinil on MS Related Fatigue, **S. Kirzinger**, J. Phillips and A. Siegwald. Denver, Colorado 28-31 May 2008

Consortium of Multiple Sclerosis Centers 22nd Annual Meeting

S35: Physical and Patient Reported Outcomes in Multiple Sclerosis, **S. Kirzinger**, M. Nichol and J. Jones, Denver, Colorado 28-31 May 2008

European Neurological Society eighteenth Meeting

P334: Predicting Neuropsychological Recommendation in Multiple Sclerosis, **S. Kirzinger**, J. Jones, M. Nichol and a. Burns. Nice, France 7-11 June 2008

Poster Presentations: Local/Regional Meetings:

Principle Investigator:
(unless otherwise noted)

1991 - 1994 Cognex Treatment
IND Study # 970-58

1993 Imitrex Post Marketing Study
CRO: PACT

1994 Cognex Rechallenge
Post Marketing Study

1993 - 1994 Quality of Life in Epilepsy
Felbatol Post Marketing Study

1994 - 1995 Gabapentin Phase III
Clinical Trials
Protocol # 945-090
CRO: Pharmaco LSR

1995 Adjunctive Lamictal in Epilepsy and
Response to Treatment
Post Marketing Study

1995 - 1996 Study of Neurontin: Titration to Effect,
Profile of Safety
Post Marketing Study
Protocol 945-193

1995 - 1996 LESO2 Protocol-North American
Ischemic Stroke/Eliprodil Study

1996 - Cognex Neuro-Psychiatric Testing and
Assessment of Caregiver Time
CONTACT: Post Marketing Study

1996-1997 Donepezil Efficacy and Safety
In Mild to Moderate Alzheimer's Disease

1997 Efficacy and Safety of Lubeluzole
In Treatment of Acute Ischemic Stroke

1997 Use of VML-251
In Acute Treatment of Migraine

1997 Use of Topiramate as Monotherapy
For Partial Seizures

1997 Use of Gabapentin as Monotherapy
For Partial Seizures

1997 Rufinamide as Adjunctive Therapy
In Adults with Inadequately Controlled
Partial Seizures

1997 Donepezil
To Treat Mild to Moderate Cerebrovascular
Dementia

1997 Naratriptan
Treatment of Acute Migraine

1998 Morphine Sulfate
With Dextromethorphan
To treat chronic pain

1998 Clomethiazole
For treatment of Acute Ischemic, Hemorrhagic
And t-PA Treated Strokes

1998 Pregabalin
Adductive Therapy for Partial Seizures

1998 Knoll Pharmaceutical Company
Treatment of Chronic Pain
Protocol No. DO-119

1999 Rufinamide 039
Monotherapy Study of Rufinamide in Patients
With Recent Onset Partial Seizures

1999 Tramadol - SR
Treatment of Non-Malignant Chronic Pain

1999 Imitrex IMPACT Study
Measuring Preference and Comparing
Treatment Study

1999 Oxcarbazepine
Safety and Therapeutic Effect of
Oxcarbazepine in Patients With
Partial Seizures

1999 Topiramate
Treatment of Patients with
Diabetic Neuropathy

1999 Topiramate
Treatment of Patients with Newly Diagnosed
Or Recurrent Epilepsy

1999 Lamictal
Trial to Assess and Redefine Global
Epilepsy Treatment

2000 Nefiracetam
Treatment in Patients with Post-Stroke Depression

2000 YM872
Safety in Ischemic Stroke Patients within 24 Hours
Of Enrollment

2000 Entacapone
Tolerability and Effect in Parkinson's Subjects
With End-of-Dose Wearing Off Symptoms

2000 Levetiracetam
Safety and Efficacy in Patients with Treatment-
Resistant, Partial-Onset Epilepsy

2000 Dilaudid-CR
Efficacy, Safety, and Impact on Quality of Life in
Patients with Chronic Low Back Pain

2000 Oxcarbazepine
Evaluation of Monotherapy in Clinical Practice
Novartis

2000 MT100
Safety and Efficacy in Subjects with Acute Migraine
Attacks

2000 Topamax
Topamax Action of Co-Therapy on Tolerability in
The Clinical Setting

2000 Clonidine Gel

Treatment of Painful Diabetic Neuropathy

2000 Betaseron
Satisfaction Trial in Educated Multiple Sclerosis
Patients (Best Trial) - Berlex

2000 Novantrone
Registry to Evaluate Effects in Worsening Multiple
Sclerosis Patients

2000 Pregabalin
Treatment for Relief of Pain Associated with
Diabetic Peripheral Neuropathy

2000 Pregabalin
Efficacy Study in Patients with Chronic Cervical
Radiculopathy

2000 YM872
Effects of YM872 on Lesion Volume as Measured
By Diffusion, Perfusion and Flair MRI in Acute
Ischemic Stroke Patients

2000 YM872
Neurologic Function and Disability Evaluations in
Acute, Ischemic Stroke Patients Given Tissue
Plasminogen Activator Plus YM 872 or Tissue
Plasminogen Activator Plus Placebo

2000 Tiagabine Hydrochloride
Safety Assessment of Two Packaging Formats and
Dosing Regimens in Subjects with Partial-Onset
Seizures

2000 Copaxone® Autoject® Device
Trial for Adults with Relapsing/Remitting MS to
Evaluate for the Relative Tolerability and Ease of
Copaxone® Self Injection with Copaxone® Autoject
Versus the Conventional Self-injection Method.

2001 AIMS
Efficacy Study of Two Therapies (Acetaminophen and
Prednisone) In Managing Flu-Like Symptoms
Associated with Avonex® Treatment in Relapsing
MS Patients

2001 CARE
Compliance Assessment for Reminyl

2001 TIME
Comparison Study of a Stratified Care Treatment
Regimen Based on Migraine Disability Versus
Standard Therapy for Acute Treatment of Migraine

2001 Rebiject™
Tolerability Comparison Study of Rebif Injection
With Rebiject™ Mini Versus Without Rebiject™
Mini in Relapsing-Remitting MS Patients

2001 BMS – 188667
Evaluation Study of the Preliminary Efficacy,
Pharmacokinetics and Immunogenicity of BMS-188667
In Subjects with Relapsing-Remitting MS

2001 Argatroban Injection
Safety and Efficacy Assessment of Argatroban
Injection in Patients with Acute Ischemic Stroke

2001 Galantamine
Safety and Efficacy Evaluation of Galantamine in
The Treatment of Dementia Secondary to Cerebro-
Vascular Disease

2001 SNK-860
Dose-Finding Study of SNK-860 in Subjects with
Diabetic Neuropathy

2001 SNK-860 Ext
Safety and Efficacy Study of Long Term
Administration of a 3mgs Dose of SNK-860 in
Subjects with Diabetic Neuropathy

2001 Cognishunt™ CNS Fluid System
An Investigation of the Safety and Effectiveness
Of the Cognishunt™ CNS Fluid System in Patients
With Alzheimer's Disease

2001 Zonisamide
Monotherapy Study of Zonisamide for Establishing

Dose-Response, Safety and Efficacy in Patients with Newly Diagnosed Epilepsy

2001 Axert™

Efficacy and Tolerability Outcomes Associated with Use Of Almotriptan Malate in Migraine Patients

2001 Imitrex®

Trial to Assess Migraine Patient Satisfaction with Imitrex® Tablets, 100 mgs.

2001 Topamax®

Comparative Study of the Efficacy and Safety of Topamax® Tablets Versus Placebo for the Prophylaxis Of Migraine

2002 Rotigotine CDS Patch

Efficacy and Safety Study of the Rotigotine CDS Patch In Subjects with Early Stage, Idiopathic PD

2002 Rotigotine CDS Patch

Efficacy and Safety Study of Rotigotine CDS Patch in Subjects with Advanced Stage, Idiopathic PD Who Are Not Well Controlled on Levodopa

2002 Lamotrigine

Efficacy and Safety Study in Subjects with Painful Diabetic Neuropathy

2002 Lamotrigine

Efficacy and Safety Study in Subjects with Peripheral Neuropathic Pain

2002 Donepezil Hydrochloride

Efficacy, Safety, Tolerability Study in Patients with Vascular Dementia

2002 Betaseron®

Safety and Tolerability Study of High Dose Interferon in Patients with Relapsing-Remitting Multiple Sclerosis

2002 Fatigue Study

Database Assessment from an MS Center

2003 Rebif Influenza Vaccination Study
Serono

2003 Pre-Beyond Study
Berlex Laboratories

2004 BEYOND: Betaseron Efficacy
Yielding Outcomes of a New Dose
Berlex- Schering AG

2004 Protocol SP754
Schwarz Pharma

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (400 and 600mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization, Principal Investigator.

2005 Fatigue Reported by MS Patients and Response to Modafinil: Assessment from an MS Center Disease Management Database, Principal Investigator.

2005 Protocol SP756
Schwarz Pharma

An Open-Label Extension Trial to Determine Safety and Efficacy of Long-Term Oral SPM927 in Patients with Partial Seizures, Principal Investigator.

2005 Protocol SP742
Schwarz Pharma

A Multi-center, Randomized, Double-blind, Placebo controlled Trial to Assess the Efficacy and Safety of 200,400,and 600mg/day SPM 927 in Subjects with Painful Distal diabetic Neuropathy, Principal Investigator.

2005 Protocol SP745
Schwarz Pharma

A Multi-center, Open-label, Follow-on Trial to assess the Long-term Safety and Efficacy of SPM 927 in subjects with painful Diabetic Neuropathy, Principal Investigator.

2005 Protocol 6002-US-018
Kyowa Pharmaceutical, Inc.

A 12 week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter, Fixed Dose-Response Study to evaluate the Efficacy and Safety of

Rev. December 2008

10,20,and 40 mg/d Oral Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Response Complications of Levadopa/Carbidopa Therapy, Sub-Investigator.

2005 Protocol 6002-INT-001

Kyowa Pharmaceutical, Inc.

A Long term, Multicenter, Open Label, Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's disease in Patients with Motor Complications on LevadopaTherapy, Sub-Investigator.

2005 Protocol No.: TVP-1012-A001-201

Eisai Medical Research, Inc.

A 1-year, double-blind, randomized, placebo-controlled study of Rasagiline 1mg and 2mg added to Aricept® 10 mg daily in patients with mild to moderate dementia of the Alzheimer's type, Principal Investigator.

2005 Protocol: U2787g

Genentech, Inc.

A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (MabThera®/Rituxan®) in Adults with Relapsing-Remitting Multiple Sclerosis, Principal Investigator.

2006 Protocol 008-05-AVX

Biogen Idec

Impact of Neutralizing Antibodies on Interferon Responsive Genes Highlights Biomarker Response – The INSIGHT Study, Principal Investigator

2006 Protocol A5451003/IMP 25695

Pfizer/Serono

Assessment of Interventions to Decrease Injection Site Reactions with Subcutaneous Interferon Beta Treatment (ASSIST - Redness Study), Principal Investigator.

2006 – Protocol #PM028

Teva Neuroscience, Inc.

A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Multiple Scheduled Neutralizing Antibody Testing on Treatment Patterns versus Usual Care in High-Dose Interferon Treated Subjects, Principal Investigator.

2007 – Protocol #27133

Serono, Inc

A randomized, multicenter, two arm, open label, 12 week phase IIIb study to evaluate the tolerability of Rebif® (Interferon (IFN) beta-1a) new formulation and Betaseron® (Interferon (IFN) beta-1b) in interferon-naïve subjects with relapsing remitting multiple sclerosis; followed by a single-arm, 24 week, Rebif®-only safety extension. Principal Investigator

2007 – Protocol #C32322

UCB S.A., Inc

Double-blind, placebo-controlled, randomised, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks. Principal Investigator

2007 – Protocol # E2007-A001-302

Eisai Medical Research, Inc.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations.

2007 – Protocol #C117

NeurogesX, Inc

A multicenter Randomized, Double Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia. Principal Investigator

2007 – Protocol #AC-3933-271

Dainippon Sumitomo Pharma Co., Ltd.

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults with Mild to Moderate Alzheimer's Disease. Principal Investigator

2007 – Protocol #6002-US-025

Kyowa Pharmaceutical, Inc.

An Open-Label, Multicenter, Study of the Continued Safety of Istradefylline in Subjects With Parkinson's

Disease Who Have Recently Completed One Year of Treatment With Istradefylline. Sub-Investigator

2007 – Protocol #309363

Bayer HealthCare (formerly Berlex Lab)

International, Multicenter, Phase IIIb Study of

Subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with

(Phase A) Double-blind Betaseron/Betaferon 250 µg or 500 µg or open-label Betaseron/Betaferon 250 µg and

(Phase B) Open-label Betaseron/Betaferon 500 µg

Short title: BEYOND Follow-up

2007 – Protocol #2007-00

Opexa Therapeutics, Inc., A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin $\tau\mu$ In Subjects with Clinically Isolated Sundrome or Relapsing-Remitting Multiple Sclerosis (TERMS).

Principal Investigator

2007 – Protocol # CFTY720D2309

Novartis, Inc., A 24-Month Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 0.5mg and 1.25mg. Fingolimod (FTY 720) Administered Orally Once Daily Versus Placebo in Patients with Relapsing-Remitting Multiple Sclerosis. Principal Investigator.

2007 – Protocol # MBP8298-SP-03

BioMS Technology, Inc. A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis (MAESTRO-03). Principal Investigator.

2008 – Protocol #CAMMS323. Genzyme Corp. A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis (CARE-MS I). Principal Investigator.

2008 – Protocol # CAMMS32400507. Genzyme Corp.

Rev. December 2008

A Phase 3, Randomized, Rater-and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High- Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Relapsed On Therapy (CARE-MS II). Principal Investigator

2008 – Protocol #109MS302. Biogen Idec, Inc. A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (CONFIRM). Principal Investigator.

2008 – Protocol #101MS402. Biogen Idec, Inc. TYGRIS: TYSABRI® Global Observational Program in Safety. Principal Investigator.

2008 – Protocol #001-06-NAT. Biogen Idec, Inc. ENER-G (Multi-center, Open-Label Study to Evaluate the Effects of Natalizumab Treatment on Fatigue and Cognition in Subjects with Relapsing Forms of MS). Principal Investigator.

2008 – Bayer Healthcare, Inc. Exploratory Study of the Timing of Multiple Sclerosis Symptoms. Co- Principal Investigator.

Research Income paid to Kentucky Neuroscience Research to date from the above studies:

2004:	\$50,743.37
2005:	\$201,619.06
2006:	\$283,248.99
2007:	\$290,616.90
2008:	\$64,549.51

Total **\$890,777.62**

Research and Program Grants:

2004: Berlex Pharmaceuticals Inc. Patient Educational Grant to MS Care Center Program University of Louisville	\$15,000
Berlex Pharmaceuticals Inc. Healthy Steps Program Grant	\$25,000
Biogen-Idec Multiple Sclerosis Fellowship Grant	\$75,000
Teva Neuroscience Multiple Sclerosis Fellowship Grant	\$50,000
School of Medicine Research Foundation Summer Research Scholar	\$3,000
2005: Teva Neuroscience Multiple Sclerosis Fellowship Grant	\$25,000
School of Medicine Research Foundation Summer Research Scholar	\$3,000
2007: Consortium of MS Centers Medical Student Summer Research Scholarship	\$5,000
Bayer Healthcare, Cognitive Function in MS Grant	\$44,100
Department of Defense, Office of U.S. Army Research W81XWH-07-0185, Co-Investigator 2% effort	
Translational Research Program in Composite Tissue Allograft Transplantation	\$674,266
2008: Department of Defense, Office of U.S. Army Research W81XWH-07-0185, Co-Investigator 2% effort	
Translational Research Program in Composite Tissue Allograft Transplantation	\$773,733
Bayer Healthcare ISS Grant, Role of Hormonal Regulation In MS Exacerbations: Exploratory Study of Timing of	

MS Symptoms, Co- Principal Investigators C. Corbitt, Biology and S. Kirzinger, Neurology	\$40,320
Consortium of MS Centers Summer Medical Student Research Scholarships: 2@\$5,000	\$10,000
Bayer Healthcare ISS Grant, Cognitive Assessment of MS Patients	\$96,500

CLINICAL SERVICE: Multiple Sclerosis Care Center Program

The University of Louisville MS Care Center Program was established in January, 2004, to provide clinical care and research studies to the Multiple Sclerosis population in the Greater Louisville area. Moving to the Department of Neurology after eighteen years in private practice was done so that the care of MS patients could be reestablished after several years of absence. In addition it allowed me to extend my interest in clinical research and practice in the MS arena which were both being limited by my private practice group responsibilities. The MS Care Center Program has received no direct support from the School of Medicine or the Kentucky –Southeast Indiana Chapter of the National MS Society.

The MS Care Center Program has operated two ongoing MS Centers offering multidisciplinary assessments of MS clients since its inception. The MS centers are now located at Baptist Hospital East and the new U of L Health Care Outpatient Facility. The patient population visit numbers seen at the Centers have grown from 1127 in 2004 to 1430 in 2007. Patients are seen at each center two days per week and clinical research patients are seen at Kentucky Neuroscience Research of University Neurologists, PSC. one day weekly.

The MS Care Center Program has provided ongoing patient education through its monthly Newly Diagnosed Program, the monthly Healthy Steps Programs, and its quarterly Patient Educational Series. The Center has been able to provide an Advanced Training Series for Pharmaceutical representatives working in the MS field. The Care Center Program has established a one to two year MS Fellowship available yearly and has trained one fellow in 2007. At the present time the MS Care Center program is staffed by a medical assistant, a nurse practitioner and a neurologist. Research support is provided through Kentucky Neuroscience Research. Other clinical duties consist of General Neurology Service coverage at University Hospital and Norton's Hospital 2 months per year at the present time. The General

Neurology Clinic at the Ambulatory Care Building is also covered every two out of twelve weeks.

Publications:

Peer-reviewed:

Kirzinger, S.S. and Fonda, M. Journal of Experimental Biology, Volume 18, 1978.

Magner, J.R., **Kirzinger, S.S.** and Spector, J., Viral Encephalitis: Neuropsychological Assessment in Differential Diagnosis and Evaluation of Sequela, International Journal of Clinical Neuropsychology, Volume 8 (3): 1217-132, 1986

Corwin, H.M. and **Kirzinger, S.S.**, Neurological Evaluation of Occupational Hand Pain, Occupational Medicine: State of the Art Reviews, 4 (3):393-403, 1989

Harter, B.T., Jr., McKiernan, J.E., Jr., **Kirzinger S.S.** et al., Carpel Tunnel Syndrome: Surgical and Nonsurgical Treatment, Journal of Hand Surgery, 18 (4): 734-739, 1993.

B.J. Hurwitz et al, Tolerability and Safety Profile of 12 and 28 Week Treatment with Interferon Beta-1b 250ug versus 500ug QOD in Patients with RRMS, Clinical Therapeutics, 30 (6): 1102-1112, 2008

Pending Publication:

S. Kirzinger, A. Siegwald and A. Crush, Fatigue and Effect of Disease Modifying Therapy. (Submitted)

S. Kirzinger et al, A Study of the Relationship between Disease Modifying Therapy and Depression in MS. (In Preparation)